Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma
| Autor: | Kornelija Miše, Ivana Šegrt, Anita Tolic Biocina, Emilija Lozo Vukovac, Ivan Škopljanac |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
medicine.medical_specialty Chemotherapy Palliative care Performance status business.industry medicine.medical_treatment medicine.disease Chemotherapy regimen Pulmonology Pemetrexed malignant pleural mesothelioma cisplatin pemetrexed chemotherapy palliative care survival Internal medicine medicine Mesothelioma business Survival analysis medicine.drug |
| Zdroj: | Pleural and Mediastinal Malignancies. |
| DOI: | 10.1183/13993003.congress-2018.pa2894 |
| Popis: | Introduction: Malignant pleural mesothelioma is a rare tumour commonly associated with asbestos exposure however with increasing incidence and poor survival. The standard first-line chemotherapy regimen is the combination of cisplatin and pemetrexed, with median overall survival of ̴ 13 months. Other therapeutic options like surgery, radiation and immunotherapy are currently limited therefore patient's performance status and histological subtype are the only prognostic factors (Scherpereel A. et al. EurRespir J 2010 ; 35: 479-95, Scherpereel A. EurRespir J.2017 Mar 15 ; 49(3). Aim and Objectives: The aim of study was to compare the patient's survival depending on whether they received chemotherapy or not. Methods: We identified retrospectively 24 patients diagnosed with pleural mesothelioma in Department of Pulmonology, Clinical Hospital Center Split, Croatia evaluating their management, whether they were treated by cisplatin/pemetrexed or solely palliative care as a result of poor performance status or refusal of any specific treatment. Kaplan-Meier survival analysis was used (MedCalc Software ver. 18). Results: The overall median survival (OS) time was 14, 6 months. A pronounced OS benefit for palliative care versus cisplatin/pemetrexed was observed, 17 vs 8 months, respectively ; HR, 0, 3665 ; 95% CI, 0, 14 to 0, 90 ; P = 0, 0047, Fig. 1. Conclusions: Chemotherapeutic treatment did not show better outcomes than solely palliative treatment. Future prospective randomized controlled studies are necessary to optimize the treatment of malignant mesothelioma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|